Quick Answer
Niagen Bioscience, Inc. reported Total Revenue of $129.42 million for fiscal year 2025.
Niagen Bioscience, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $129.42M +29.9% |
$99.60M +19.2% |
$83.57M +16.0% |
$72.05M +6.8% |
$67.45M +13.8% |
$59.26M +28.0% |
| Net Income | $17.38M +103.3% |
$8.55M +273.1% |
-$4.94M +70.1% |
-$16.54M +39.0% |
-$27.13M -36.2% |
-$19.93M +38.0% |
| Diluted EPS | $0.20 +81.8% |
$0.11 +257.1% |
-$0.07 +70.8% |
-$0.24 +40.0% |
-$0.40 -21.2% |
-$0.33 |
| Total Assets | $106.41M +55.8% |
$68.28M +24.2% |
$54.96M +1.7% |
$54.06M -6.5% |
$57.84M +50.8% |
$38.36M -4.7% |
| Cash and Equivalents | — | — | — | — | $28.22M +69.0% |
$16.70M -11.2% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $76.53M +66.0% |
$46.09M +62.0% |
$28.46M -0.8% |
$28.67M -9.6% |
$31.73M +93.2% |
$16.42M -19.7% |
| R&D Expense | $6.33M +5.2% |
$6.02M +21.3% |
$4.96M +2.7% |
$4.83M +25.9% |
$3.83M +12.2% |
$3.42M -22.7% |
| Operating Income | $16.28M +110.7% |
$7.73M +238.0% |
-$5.60M +69.9% |
-$18.63M +31.2% |
-$27.07M -36.4% |
-$19.85M +36.6% |
| Gross Profit | $83.19M +35.1% |
$61.59M +21.3% |
$50.78M +18.7% |
$42.80M +3.2% |
$41.49M +17.6% |
$35.27M +36.9% |
| Shares Outstanding | 79.71M +3.1% |
77.33M +3.1% |
74.98M +0.6% |
74.57M +9.5% |
68.13M +10.1% |
61.88M +3.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $33.99M | +32.9% | +9.2% |
| Net Income | September 30, 2025 | $4.58M | +143.8% | +26.8% |
| Diluted EPS | September 30, 2025 | $0.05 | +150.0% | +25.0% |
| Total Assets | September 30, 2025 | $98.14M | +73.6% | +7.2% |
| Cash and Equivalents | March 31, 2022 | $20.99M | -53.0% | -25.6% |
| Long-Term Debt | September 30, 2016 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $70.68M | +105.6% | +10.1% |
| R&D Expense | September 30, 2025 | $1.79M | +39.1% | +14.6% |
| Operating Income | September 30, 2025 | $4.24M | +164.4% | +33.0% |
| Gross Profit | September 30, 2025 | $21.93M | +35.0% | +8.4% |
| Shares Outstanding | September 30, 2025 | 79.64M | +4.8% | +0.1% |
- Niagen Bioscience, Inc. reported Total Revenue of $129.42 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +29.9% in Total Revenue compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Net Income of $17.38 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +103.3% in Net Income compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Diluted EPS of $0.20 per share for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +81.8% in Diluted EPS compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Total Assets of $106.41 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +55.8% in Total Assets compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Cash and Equivalents of $28.22 million for fiscal year 2021.
- Niagen Bioscience, Inc. showed an increase of +69.0% in Cash and Equivalents compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Long-Term Debt of $0.00 for fiscal year 2016.
- Niagen Bioscience, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Stockholders Equity of $76.53 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +66.0% in Stockholders Equity compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported R&D Expense of $6.33 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Operating Income of $16.28 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +110.7% in Operating Income compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Gross Profit of $83.19 million for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +35.1% in Gross Profit compared to the prior fiscal year.
- Niagen Bioscience, Inc. reported Shares Outstanding of 79.71 million shares for fiscal year 2025.
- Niagen Bioscience, Inc. showed an increase of +3.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: